---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-000099"
form_type: "8-K"
ticker: "HBIO"
cik: "0001123494"
company_name: "HARVARD BIOSCIENCE INC"
filed_at: "2024-01-05T23:59:59+00:00"
generated_at: "2026-06-07T02:55:05.815142+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Harvard Bioscience prelim FY2023 revenue ~$112.3M; includes $5.1M discontinued product headwind

## Summary
- Preliminary unaudited FY2023 revenue estimate of ~$112.3M, down from $113.3M in FY2022, with $5.1M net headwind from discontinued products.
- Adjusted EBITDA for YTD Q3 2023 was $10.9M (13% of revenue), up 53% vs prior year; FY2022 adjusted EBITDA margin was 9.6%.
- Company cites Covid portfolio optimization and supply chain challenges as revenue headwinds.
- Guidance from Q3 2023 earnings (Nov 7, 2023) was for FY23 revenue down 11-14%; this presentation does not reaffirm guidance.

## SEC filing metadata
- accession: 0001171843-24-000099
- form_type: 8-K
- ticker: HBIO
- cik: 0001123494
- company_name: HARVARD BIOSCIENCE INC
- filed_at: 2024-01-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1123494/000117184324000099/0001171843-24-000099-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1123494/000117184324000099/f8k_010524.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-000099
- JSON: https://secwatch.observer/filing/0001171843-24-000099.json
- Plain text: https://secwatch.observer/filing/0001171843-24-000099.txt

## Key facts
- Earnings Releases
  HARVARD BIOSCIENCE INC reported full year 2023 results: revenue ~ $112.3M incl. $5.1M net discontinued*.
  - Period: full year 2023
  - Revenue: ~ $112.3M incl. $5.1M net discontinued*
  - Result: preliminary results
  source text: Est. FY’23 Revenue: ~ $112.3M incl. $5.1M net discontinued*
  evidence_url: https://www.sec.gov/Archives/edgar/data/1123494/000117184324000099/0001171843-24-000099-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.